NasdaqGM:PTGXBiotechs
Protagonist Therapeutics (PTGX) As MIMRYLO Approval Reshapes The Valuation Debate
Protagonist Therapeutics (PTGX) is in focus after partner Takeda secured U.S. FDA approval for MIMRYLO, a hepcidin mimetic peptide for polycythemia vera, triggering US$275 million in milestone payments to the company.
The FDA approval news for MIMRYLO comes after a strong run for Protagonist Therapeutics, even though the stock has cooled in the very short term, with the share price down 3.46% over the last day and 6.47% over the past week. At a latest share price of US$144.33, the stock still...